TRIM32 and non-small cell lung carcinoma: TRIM32 can maintain mitochondrial membrane potential after cisplatin treatment and reduce the generation of reactive oxygen species (ROS), reduce cisplatin sensitivity, and maintain Mitochondrial Membrane Potential Difference (MMPD) in non-small cell lung cancer (NSCLC) cells.